Canada: PMPRB Decision Creates Uncertainty For Patentees

Last Updated: November 8 2017
Article by Sebastien Pepin, Thomas J. Timmins and David Torchetti

Most Read Contributor in Canada, October 2018

On September 27, 2017, a two-member Hearing Panel of the Patented Medicine Price Review Board (PMPRB) ruled that the ultra-rare disease drug Soliris® (eculizumab), manufactured by Alexion Pharmaceuticals Inc. (Alexion), was "excessively priced." The Panel ordered both a reduction of the price of Soliris going forward and required Alexion to pay past "excessive" revenues.

A surprising and unprecedented feature of the decision was the application of an entirely new test, the "lowest international price comparison test" ("LIPC test") to determine whether the price of Soliris was excessive. The Panel ruled that the LIPC test, a test of its invention, should apply to the introductory price of Soliris, and to the price of Soliris going forward, even though the test cannot be found in any of the Guidelines published by the Board. An LIPC test has never been applied previously to any other drug sold in Canada and was invented by the Panel in the case to apply only to Alexion.

In the decision, the Panel ruled that past "excessive" revenues would be calculated based on the highest international price comparison test (HIPC test) found in the Guidelines. The Panel also refused to permit any offsets for various rebates and other benefits provided by Alexion in Canada.

Background

Under the Patent Act (Act) and Patented Medicine Regulations (Regulations), the PMPRB can order manufacturers of patented drugs to reduce the average price at which a drug is sold in Canada to a price not considered "excessive." The Board can also order a manufacturer to pay the government any "excessive" revenue generated above what the Board considers a non-excessive price. The factors considered by the Board when determining whether a price is excessive are found in section 85(1) of the Act. Typically, the factors are interpreted by Board staff based on the Board's published Guidelines.  The Guidelines, however, are merely presumptive in application. If compelling evidence is advanced to rebut the presumption that the Guidelines should apply, a hearing panel can depart from the Guidelines in individual cases where the Guidelines may not, in the panel's view, adequately apply the statutory factors in the Act.

Soliris is a "breakthrough" drug for two ultra-rare and usually fatal diseases. The only applicable test found in the Guidelines for breakthrough drugs is the "median international price comparison test" (MIPC test) for the introductory price, and the HIPC test for the price in subsequent years. Under these tests, the price of a drug is compared to the price of the same drug in a "basket" of seven countries specified in the Regulations, and held to be excessive if the price is higher than the median international price (at introduction) or the highest international price (in subsequent years).

In 2010 and 2011, the Board stated that the introductory price of Soliris in 2009 was within Guidelines. The 2009 introductory price has never been increased nor has the medicine's price been reduced in any of the comparator countries. Fluctuations in international exchange rates between 2012 and 2015 made it appear, however, that the Canadian price was the highest international price, even as the Canadian price was falling in real terms given increases in the (Canadian) Consumer Price Index. 

In 2015, the Board "requested" that Alexion "voluntarily" lower its price. Alexion declined on the basis that the price was only "excessive" because of exchange-rate fluctuations beyond the Company's control that did not affect consumers in Canada. Alexion also asked the Board to take into account the sizable rebates provided by the company to provincial public drug plans, who pay a substantial number of the claims made by users of Soliris.

The Decision

In the original Statement of Allegations, Board Staff took the position that the Guidelines should be strictly applied. Before the hearing was originally scheduled to commence, however, Board staff shifted their liability theory to assert that the price of Soliris in Canada should be the lowest price of the medicine in the seven comparator countries.

The Panel ultimately accepted the new 'theory'. In doing so, they relied on what they characterized as the Board's "consumer protection mandate", which they found justified a departure from the Guidelines. The essential rationale for their decision was that if Alexion were willing to sell Soliris at the "lowest international price" (in this case, the UK price), the company must be able to "cover its costs and earn a normal rate of return." In essence, the Panel found no reason that Canadians should pay more than the lowest international price for Soliris.

Despite rejecting Alexion's arguments that application of the newly-formulated LIPC test would be unfair and retroactive, and despite holding that the price of Soliris had been "excessive" since introduction based upon the LIPC test, the Panel concluded it would not be "appropriate, fair and consistent with the Panel's mandate" to apply the LIPC test to calculate past "excessive revenues." Instead, the Panel ordered that calculation of past "excessive revenues" would be based on the HIPC test found in the Guidelines.

The Panel also rejected Alexion's arguments that the HIPC test should not apply, and any presumption of excess revenues should not be made in the face of exchange rate fluctuations beyond Alexion's control. The Panel insisted that the Guidelines provide "advance notice" to patentees that exchange rate fluctuations are at a patentee's risk. No patent abuse was found by the Panel: Alexion's good conduct was irrelevant.

The Panel also rejected all of Alexion's arguments for offsets to the price based on the large rebates paid to the provincial insurers and/or to Alexion's wholesaler.

Concerns Raised by Decision        

The obvious concern for the industry raised by the decision is that the Panel  departed from the Guidelines to create its new LIPC test, which could apply to all patentees. Indeed, the Panel  expressly noted that it was not applying any "special scrutiny" to Alexion. The reasons given by the Panel for applying the new test to Alexion—that the Board's  "consumer protection mandate" required the Canadian price to be the lowest price commensurate with a patentee covering its costs and earning a "normal" rate return—are not factors found in the legislation, Guidelines, or any previous decision.  There is no reason why the same rationale cannot be applied to any or all patented medicines sold in Canada. 

Nevertheless, the Panel relied on the Guidelines as providing reasonable notice to patentees that the company, and other patentees, bore the risks of exchange rate fluctuations. At the same time, however, the Panel applied its new LIPC test to the price of Soliris that is nowhere to be found in the Guidelines, even though Alexion could never have known about the test when it introduced Soliris on the Canadian market.  The new test appears to apply universally to patented drugs sold in Canada and means that patentees have no certainty that a price that is within Guidelines upon introduction, will not find itself facing liability after the fact for "excessive" pricing at the time of introduction.

Alexion has applied to the Federal Court of Canada for a judicial review of the Panel's decision. 

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions